MONISTAT 5 (miconazole nitrate) by Personal Genomics is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida. Approved for vulvovaginal candidiasis, candidiasis, tinea cruris and 1 more indications. First approved in 1989.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
MONISTAT 5 (miconazole nitrate) is a vaginal antifungal suppository approved in 1989 for treating vulvovaginal candidiasis and other fungal infections. It exhibits fungicidal activity against Candida species through an unknown pharmacologic mechanism, with minimal systemic absorption following intravaginal administration. The 3-day suppository regimen provides comparable efficacy to 7-day topical cream formulations.
Product is in late-stage lifecycle with no current patent protection; brand team focus is likely on defensive maintenance and potential transition to generic partner models.
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Worked on MONISTAT 5 at Personal Genomics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Working on MONISTAT 5 offers limited career growth due to LOE approaching and minimal pipeline activity; roles focus on sales sustainment, pricing strategy, and generic management rather than innovation. This is a mature product assignment best suited for professionals with defensive market strategy experience or those transitioning to generics management.